Zydus Lifesciences shares in focus on USFDA nod for canine drug – News Air Insight

Shares of Zydus Lifesciences Ltd are expected to be in focus on Tuesday after its wholly owned subsidiary, ZyVet Animal Health, launched the first FDA-approved generic treatment for canine urinary incontinence in the United States.

The product, phenylpropanolamine hydrochloride tablets, marks a significant entry into the underserved animal generics market and is aimed at treating urinary incontinence in dogs, particularly aging and spayed females.

Released under the ZyVet brand, the generic is designed to provide cost-effective symptom relief while supporting long-term compliance. It comes in multiple strengths for precise dosing and is formulated to meet the clinical and practical needs of both veterinarians and pet owners.

According to the company, the launch reflects ZyVet’s mission to deliver high-quality, affordable veterinary pharmaceuticals across the U.S. Zydus highlighted that fewer than 20% of FDA-approved animal drugs have a generic version, indicating a substantial market gap. The move is expected to strengthen ZyVet’s position as a leader in affordable innovation within animal healthcare.

“Urinary incontinence affects quality of life for both pets and their families. Our phenylpropanolamine hydrochloride tablets deliver on clinical reliability and affordability, enabling veterinarians to treat more patients while maintaining client compliance. We’re proud to offer an option that removes cost as a barrier to compassionate care. With each launch, we reinforce that innovation doesn’t need a premium price – every pet should have access to high-quality treatment options,” said Punit Patel, President and CEO, Zydus Americas.

The new product follows ZyVet’s broader portfolio expansion strategy and underscores the growing importance of generic animal health products. The company emphasized that each launch aims to remove financial barriers that limit access to compassionate veterinary care.Shares of Zydus Lifesciences closed 0.8% lower at Rs 1,036.70 on BSE on Monday.Also read: SEBI’s curb on weekly F&O expiry: Feroze Azeez explains what it could mean for investors

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)